Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically ...
Haduvio is a proprietary, orally administered, extended-release formulation of nalbuphine, a mu-opioid receptor antagonist and kappa-opioid receptor agonist. It is currently being developed as a potential therapeutic to address chronic pruritus (severe itching) and persistent cough, specifically in patients suffering from idiopathic pulmonary fibrosis (IPF) and other refractory chronic cough conditions.
Price Range: N/A (Investigational drug, not yet commercially available)
Pain Points: Addresses the lack of effective, FDA-approved treatments for debilitating symptoms like persistent cough in IPF and chronic pruritus, which significantly degrade patient quality of life and have limited existing therapeutic options.
Solutions: Offers a potential novel mechanism of action to reduce cough frequency and severity, as well as pruritus, by modulating opioid receptors in an extended-release format.
Target Users: Healthcare providers treating patients with chronic, debilitating conditions such as idiopathic pulmonary fibrosis, refractory chronic cough, and prurigo nodularis.
Supply Chain
Nalbuphine hydrochloride sourcing (licensing agreement with Endo Pharmaceuticals Inc.)Clinical-stage manufacturing partnersClinical trial logistics providersRegulatory and distribution networks for clinical supply
